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Abstract 
Exercise intolerance characteristic of diseases such as chronic heart failure (CHF) and 
diabetes is associated with reduced nitric oxide (NO) bioavailability from nitric oxide synthase 
(NOS), resulting in an impaired microvascular O2 driving pressure (PO2mv: O2 delivery – O2 
utilization) and metabolic control. Infusions of the potent NO donor sodium nitroprusside 
augment NO bioavailability yet decrease mean arterial pressure (MAP) thereby reducing its 
potential efficacy for patient populations. To eliminate or reduce hypotensive sequellae NO2
- was 
superfused onto the spinotrapezius muscle. It was hypothesized that local NO2
- administration 
would elevate resting PO2mv and slow PO2mv kinetics (increased τ: time constant, MRT: mean 
response time) following the onset of muscle contractions. In 12 anesthetized male Sprague-
Dawley rats, PO2mv of the circulation-intact spinotrapezius muscle was measured by 
phosphorescence quenching during 180 s of electrically-induced twitch contractions (1 Hz) 
before and after superfusion of NaNO2 (30 mM).  NO2
- superfusion elevated resting PO2mv 
(CON: 28.4 ± 1.1 vs NO2
-: 31.6 ± 1.2 mmHg, P ≤ 0.05), τ (CON: 12.3 ± 1.2 vs NO2-: 19.7 ± 2.2 
s, P ≤ 0.05) and MRT (CON: 19.3 ± 1.9 vs NO2-: 25.6 ± 3.3 s, P ≤ 0.05).  Importantly, these 
effects occurred in the absence of any reduction in MAP (103 ± 4 vs 105 ± 4 mmHg, pre- and 
post-superfusion respectively; P ˃ 0.05).  These results indicate that NO2- supplementation 
delivered to the muscle directly through NO2
- superfusion enhances the blood-myocyte driving 
pressure of oxygen without compromising MAP at rest and following the onset of muscle 
contraction.  This strategy has substantial clinical utility for a range of ischemic conditions. 
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1 
Introduction 
Sustained muscle contractions require a robust and appropriate hyperemic response that 
is contingent upon arteriolar vasodilation increasing muscle O2 delivery (Q̇O2) in proportion to 
the elevated O2 demands (V̇O2). It is also important to recognize that the instantaneous Q̇O2/ 
V̇O2 ratio sets microvascular O2 pressures (PO2mv) that are crucial for blood-myocyte O2 flux 
and also the intracellular PO2 which influences metabolic control (29, 50). 
Within the spectrum of vasoactive mediators for the exercise hyperemia nitric oxide (NO) 
is a key player. Thus, blockade of the endogenous endothelial NO synthase (eNOS) and/or 
neuronal NOS (nNOS) systems reduces exercising muscles(s) blood flow and Q̇O2 (8, 28) 
lowering PO2mv (22) and impairing function. In diseases such as chronic heart failure 
dysfunction of the NOS system reduces NO bioavailability with the resultant decrease of PO2mv, 
especially in the transient phase immediately following the onset of contractions, slows V̇O2 
kinetics and contributes to muscle dysfunction characteristic of chronic heart failure (CHF) (15, 
21, 26, 44). 
Given the reduced capacity for endogenous NO production in disease, possibly as a 
consequence of tissue hypoxia and elevated reactive oxygen species which constrain NOS 
function, there has been substantial interest in providing exogenous NO precursors such as 
sodium nitroprusside (SNP) and inorganic nitrate/nitrite (NO3
-/NO2
-) (37, 54). A particularly 
attractive feature of the NO3
-/NO2
- pathway is that the pathological muscle hypoxia found in 
CHF and other patients promotes NO2
- reduction to NO and hence enhances Q̇O2 locally without 
compromising systemic blood pressure as might be expected for systemic vasodilators such as 
SNP or hydralazine, for example (51, 52). Recently, beetroot (BR) juice has been advocated as 
an NO3
-/NO2
- source that reduces mean arterial pressure, enhances muscle Q̇O2 and PO2mv, and 
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improves muscle contractile function and efficiency (19, 20, 33). Unfortunately, after absorption 
in the gut the NO3
--NO2
- reduction requires salivary gland NO3
- secretion and the participation of 
commensal bacteria in the oral cavity before resorption into the blood stream as circulating NO2
-. 
These steps typically take hours to raise plasma [NO2
-] (53) and can be blocked by mouthwash-
induced bactericide (39). 
Given these limitations the utility of increasing vascular [NO2
-] more directly has been 
considered (38). However the results have been controversial with up to 36 µmol/min NO2
- 
infused into the forearms of healthy subjects proving ineffective (34). Arguing that hypoxia is 
crucial for the NO2
--NO reduction Maher and colleagues (38) subsequently demonstrated that 
direct arterial infusions into the resting forearm of subjects breathing 12% O2 (estimated arterial 
PO2 48-55 mmHg) induced a robust arterial vasodilation. These are precisely the conditions 
extant in the microvasculature of contracting muscles. Specifically, in the rat during exercise 
muscle PO2mv falls to ~20 mmHg in muscles comprised predominantly of slow twitch fibers or 
~10 mmHg in fast twitch muscles (4, 40). Moreover, we have demonstrated that, when NO 
bioavailability is reduced by CHF (23) or NOS blockade (18), NO2
- infusions induce a robust 
increase in muscle Q̇O2 that is especially pronounced in fast twitch muscles. 
Because enhanced NO bioavailability has the potential to both elevate Q̇O2 and reduce 
V̇O2 direct measurements of PO2mv are necessary to evaluate the efficacy of NO2- treatment to 
enhance blood-myocyte O2 flux. Moreover, because V̇O2 demands change most rapidly within 
the first minute or so of contractions we argue that assessing the efficacy of NO2
- to raise PO2mv 
across this interval with high temporal fidelity is crucial. In the rat spinotrapezius muscle we 
therefore tested the hypothesis that local NO2
- superfusion under normoxic conditions would 
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elevate PO2mv significantly and, importantly, would do so in the absence of systemic 
hypotension.  
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Methods 
Twelve male Sprague-Dawley rats (mass = 421 ± 23 g, Charles River Laboratories, 
Wilmington, MA) were used in this investigation.  Rats were provided food and water ad libitum 
while housed in a 12/12 hr light-dark cycle facility at Kansas State University.  All procedures 
were approved by the Institutional Animal Care and Use Committee of Kansas State University 
and conducted according to National Institute of Health Guidelines. 
 
 Surgical Preparation 
Rats were initially anesthetized with a 5% isoflurane-O2 mixture and subsequently 
maintained on 3% isoflurane-O2. Following cannulation of the carotid artery, a catheter (PE-10 
connected to PE-50, Intra-Medic polyethylene tubing, Clay Adams Brand, Becton, Dickinson 
and Company, Sparks, MD) was inserted into the carotid artery for measurement of mean arterial 
pressure (MAP) and heart rate (HR), and infusion of the phosphorescent probe (see below). A 
second catheter was inserted into the caudal artery for the infusion of pentobarbital sodium 
anesthesia and arterial blood sampling. Upon closing the incisions for the carotid and caudal 
catheters, rats were transitioned to pentobarbital sodium anesthesia and concentrations of 
isoflurane were removed. The level of anesthesia was regularly monitored via toe pinch and 
palpebral reflex; with anesthesia supplemented as necessary. Rats were placed on a heating pad 
to maintain a core temperature of ~38˚C (measured via rectal probe). Incisions were then made 
to carefully expose the right spinotrapezius muscle with overlying skin and fascia reflected such 
that the integrity of the neural and vascular supply was maintained (2). Using 6-0 silk sutures, 
silver wire electrodes were secured to the rostral (cathode) and caudal (anode) regions of the 
muscle. Exposed muscle tissue was superfused with warmed (38 ˚C) Krebs-Henseleit 
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bicarbonate buffered solution equilibrated with 5% CO2-95% N2. Surrounding exposed tissue 
was covered with Saran wrap (Dow Brands, Indianapolis, IN) to ensure that superfused solutions 
were confined to the spinotrapezius. The spinotrapezius muscle was selected based on its mixed 
muscle fiber-type composition and citrate synthase activity, which resembles the quadriceps 
muscle in humans (13, 35). 
 
 Experimental Protocol 
The phosphorescent probe palladium meso-tetra (4 carboxyphenyl)tetrabenzoporphyrin 
dendrimer (G2: 15-20 mg kg-1 dissolved in 0.4 ml saline) was infused via the carotid artery 
catheter. Following a brief stabilization period (~10 min), the common end of the light guide of a 
frequency domain phosphorimeter (PMOD 5000, Oxygen Enterprises, Philadelphia, PA) was 
positioned ~2-4 mm superficial to the dorsal surface of the exposed right spinotrapezius muscle 
as described previously (2). Fields containing large vessels were avoided in order to ensure that 
the measurements obtained were of principally capillary blood. PO2mv was measured at rest and 
during the 180 s contraction protocol (1 Hz, ~6V, 2 ms pulse duration) via phosphorescence 
quenching (see below) and recorded at 2 s intervals. Muscle contractions were elicited via a 
Grass stimulator (model S88, Quincy, MA). Following the contraction period, blood samples 
were taken for analysis and PO2mv was monitored to ensure that microvascular control was 
preserved and values returned to baseline. After a 30 min stabilization period NaNO2 (30 mM in 
3.0 ml Krebs-Henseleit bicarbonate buffered solution) was continuously superfused for 3 min 
along the exposed muscle. This NaNO2 dose was chosen due to the curved nature of the 
spinotrapezius muscle spanning the rib cage. Once the superfused solution is applied, the portion 
that does not diffuse into the muscle runs down the Saran wrap and onto a waste collection site. 
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Approximately 1 min following superfusion, after PO2mv stabilized, the aforementioned 
contraction protocol was repeated. Rats were then euthanized via pentobarbital sodium overdose 
(≥50 mg/kg administered into the carotid artery catheter). 
 
 PO2mv Measurement and Curve-fitting 
PO2mv was calculated using the Stern-Volmer relationship. Direct measurement of 
phosphorescence lifetime utilized in the following equation yields PO2mv (45); 
PO2mv = [ τ˚ / τ - 1] / (kQ  x τ˚) 
Where kQ is the quenching constant and τ˚ and τ are the phosphorescence lifetimes in the absence 
of O2 and at the ambient O2 concentration, respectively. For G2, kQ is 273 mmHg
-1 s-1and τ˚ is 
251 μs (16). Since the G2 phosphorescent probe binds to blood proteins, G2 is evenly distributed 
throughout plasma and compartmentalized to the vascular space (16, 43). Therefore, in vivo, the 
phosphorescence lifetimes are determined directly by O2 pressure because kQ and τ˚ do not 
change appreciably over the physiological ranges of temperature and pH (16, 45). 
Using computer software (SigmaPlot 11.0, Systat Software, San Jose, CA), PO2mv 
responses were curve-fitted from the collected PO2mv data points. Curves were fit using either 
one-component or two-component models described below: 
One component: PO2mv (t) = PO2mv (BL) – Δ PO2mv (1- e –(t – TD)/t) 
Two component: PO2mv (t) = PO2mv (BL) – Δ1PO2mv (1- e –(t – TD1)/τ1) + Δ2PO2mv (1- e –(t – 
TD2)/τ2) 
Where PO2mv(t) represents the PO2mv at any given time t, PO2mvBL corresponds to the pre-
contracting resting baseline PO2mv, Δ1 and Δ2 are the amplitudes for the first and second 
component, respectively, TD1 and TD2 are the time delays for each component, and τ1 and τ2 are 
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the time constants (i.e., time to reach 63% of the final response value) for each component. 
Appropriate fits were determined using the following criteria: 1) the coefficient of determination, 
2) sum of the squared residuals, 3) visual inspection and analysis of the model fits to the data and 
the residuals. To provide an index of the overall principal kinetics response, the first and second 
components were used to calculate MRT1 and MRT2, respectively. MRT was calculated using 
the following equations: 
One component: MRT1 = TD1 + τ1 
Two component: MRT2 = TD2 + τ2 
Where TD1, TD2, τ2 and τ2 are as described above. 
 
 Statistical Analysis 
Data are presented as means ± SE. Preliminary data were compared between 
(Superfusion vs. IA Infusion) and within groups using two-way repeated measures ANOVA 
(MAP) with Tukey’s post hoc analyses. Study results were compared within (Pre- vs. Post-
Superfusion) groups using one-way repeated measures ANOVA (MAP and HR) or paired 1- and 
2- tail Student’s t-tests as appropriate for a priori directional hypotheses (blood gases, blood 
[lactate], and PO2mv kinetics parameters). Significance was accepted at P ≤ 0.05.  
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Results 
Preliminary data (n=3) in Figures 1 and 2 indicated that NaNO2 (30 mM) during a 3-min 
superfusion protocol elevated PO2mv without significantly changing MAP.  Bolus intra-arterial 
(IA) infusion (7 mg kg-1) decreased MAP significantly and transiently decreased PO2mv within 
the initial 3-min. 
 
 Microvascular Oxygen Pressures (PO2mv)  
Within 3-min superfusion of NaNO2 PO2mv was significantly elevated (PO2mvBL; CON: 
28.4 ± 1.1 mmHg vs. NO2
-: 31.6 ± 1.2; P ≤ 0.05) (Table 1, Figure 3).  Following the onset of 
contractions, NO2
- exhibited a significantly larger PO2mv amplitude (CON: 10.5 ± 0.9 vs. NO2
-: 
12.7 ± 0.8 mmHg; P ≤ 0.05), slower τ (CON: 12.3 ± 1.2 vs. NO2-: 19.7 ± 2.2 s; P ≤ 0.05), and 
increased MRT (CON: 19.3 ± 1.9 vs. NO2
-: 25.6 ± 3.3 s; P ≤ 0.05) (Figure 4A).  As shown in 
Figure 4B, the difference in driving pressure between conditions continued for the first 40 
seconds of electrically-stimulated contractions.  
 
 Central Hemodynamics and Blood Gases 
Superfusion of NaNO2 did not significantly alter MAP or HR from pre-superfusion 
values (MAP: 103 ± 4 vs. 105 ± 4 mmHg, HR:  330 ± 10 vs. 321 ± 11 bpm, pre- and post- 
respectively; both P ˃ 0.05). Likewise, there was no significant difference in MAP or HR 
between CON and NO2
- conditions following the contraction protocol (P ˃ 0.05). Finally, there 
were no significant differences in %O2 saturation (CON: 91.5 ± 1.5 vs. NO2
-: 93.1 ± 0.7%), 
PCO2 (CON: 42 ± 2 vs. NO2
-: 41 ± 2 mmHg), or blood [lactate] (CON: 1.6 ± 0.1 vs. NO2
-: 1.6 ± 
0.2 mM) between groups (P ˃ 0.05). 
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Table 1. PO2mv parameters of the spinotrapezius muscle at rest and following the onset of 
contractions under control and NaNO2 conditions   
 
 CON NO2
- 
PO2mvBL, mmHg 28.4 ± 1.1 31.6 ± 1.2* 
Δ1PO2mv, mmHg 10.5 ± 0.9 12.7 ± 0.8* 
PO2mv(steady-state), mmHg 18.0 ± 0.9 18.9 ± 1.2 
TD1, s 7.0 ± 1.2 6.0 ± 1.6 
τ1, s 12.3 ± 1.2 19.7 ± 2.2* 
MRT1, s 19.3 ± 1.9 25.6 ± 3.3* 
Δ2PO2mv, mmHg 3.4 ± 0.5 2.9 ± 0.1 
TD2, s 78.5 ± 22.3 68.9 ± 9.5 
τ2, s 67.9 ± 7.7 77.1 ± 14.2 
MRT2, s 146.4 ± 25.7 97.3 ± 48.8 
 
Values are means ± SE.  PO2mvBL, resting PO2mv; Δ1PO2mv and 
Δ2PO2mv amplitude of the first and second components; 
PO2mv(steady-state), contracting steady-state PO2mv; TD1 and TD2, time 
delay of the first and second component; τ1, and τ2, time constant of 
the first and second component; MRT1 and MRT2, mean response 
time of the first and second component. Primary components were 
calculated for all rats (n=12).  Secondary components were present 
in 3 CON and 2 NO2
- rats. *P ≤ 0.05 vs. CON. 
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Figure 1. NaNO2 Superfusion vs. Intra-arterial Infusion on PO2mv 
Averaged PO2mv from preliminary results (n=3) during 180 s of NaNO2 superfusion (30 mM) 
and a bolus intra-arterial (IA) infusion of NaNO2 (7 mg kg
-1). Inset black box denotes the 
superfusion period. Measurements were recorded for an additional 600 s to monitor the effects of 
direct vs. systemic administration in the absence of muscle contraction. Following a plateau in 
PO2mv, there was a decline in PO2mv at the rate of -0.012 mmHg s
-1 in the superfusion condition. 
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Figure 2. NaNO2 Superfusion vs. Intra-arterial Infusion on MAP 
Preliminary results (n=3) showed that mean arterial pressure (MAP) during 180 s of NaNO2 
superfusion (30 mM) remained constant whereas a bolus intra-arterial (IA) infusion of NaNO2 (7 
mg kg-1) produced a sustained reduction in MAP by as much as ~14-15 mmHg. Data are 
presented as means ± SE. 
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Figure 3. Microvascular oxygen pressure (PO2mv) during NaNO2 superfusion 
Microvascular oxygen pressure (PO2mv) of the spinotrapezius muscle for the experimental group 
of rats (n=12) was measured every 2 s during the 180 s superfusion of 30 mM NaNO2 in Krebs-
Henseleit solution. Inset black box denotes the superfusion period. 
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Figure 4. PO2mv and MAP during contractions, and PO2mv difference between NaNO2 and 
Control 
A: Average spinotrapezius PO2mv kinetics for the experimental group of rats (n=12) during 180 s 
electrically stimulated contractions in the control condition (closed circles) and following NaNO2 
superfusion (open circles). Mean arterial pressure (closed squares) was recorded at the beginning 
and end of the contraction protocol. Data are presented as means ± SE. B: PO2mv differences for 
each 2 s measurement for the experimental group of rats (n=12) between NaNO2 and CON 
conditions during spinotrapezius muscle contractions. Note that prior to (i.e. left of) the dashed 
line, NaNO2 is significantly different from CON (P < 0.05). 
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Discussion 
The principal original findings of the present investigation demonstrate that NaNO2 
superfusion enhances the muscle PO2mv at rest (i.e. elevated PO2mvBL) and during the transition 
from rest-to-contractions, in part, by slowing the PO2mv fall (i.e. increased τ and MRT).  
Importantly, these effects occurred concomitant with stable MAP. The ability of NO2
- to enhance 
the driving pressure of O2 before and for the 40 s after the onset of muscle contractions (Figures 
4A and 4B) would be expected to potentially decrease reliance on immediate, nonoxidative 
energy pathways and delay the production of fatigue-inducing metabolic products (29, 50).  In 
disease conditions attended by cardiovascular complications, the inability to deliver O2 may 
induce ischemic damage, impair recovery and, for active skeletal muscle, constrain exercise 
performance and perhaps daily activities essential to life quality. The delivery of exogenous NO2
- 
is known to improve the central and systemic derangements prevalent in CHF (5, 37, 42) and we 
now demonstrate that it rapidly enhances peripheral control directly by circumventing the NOS 
pathway. 
 
 Microvascular Oxygen Pressure (PO2mv) Dynamics 
In skeletal muscle at rest, NaNO2 has the potential to elevate the driving pressure of O2 
from blood to myocyte (PO2mvBL) under normoxic conditions. This NOS-independent effect 
coheres with previous investigations that have administered NO precursors (20, 22, 25). With 
respect to the PO2mv elevations, these may be the consequence of increased Q̇O2, decreased 
V̇O2, or a combination of both. Q̇O2 increases with increasing [NO2-] because the one step 
reduction to NO occurs in the low PO2 environment of resistance vessels in healthy individuals 
(18, 19). The advantage of the NO2
--NO reduction is that NOS reliance is avoided, rather NO2
- is 
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reduced to NO in environments of low O2/pH via interactions with deoxyhemoglobin, tissue and 
vascular myoglobin, xanthine oxidoreductase, and aldehyde dehydrogenase. Furthermore, by 
experimental blockade of endogenous production of NO from eNOS and nNOS 
pharmacologically (L-NAME and SMTC) blood flow is reduced independent of any increases in 
sympathetic activity/vasoconstriction (10, 27)(9, 10, 27, 28). The present results clearly 
demonstrate that NaNO2 increases PO2mvBL and that the NO2
--NO reduction compliments any 
NO emanating from the intact NOS system to augment PO2mv.  The direct measurement of 
PO2mv herein extends previous observations of NO2
- induced vasorelaxation and increased Q̇O2 
in healthy subjects (11, 12, 38).  
Potentially, the increased PO2mv could also be explained by mitochondrial inhibition 
(↓V̇O2) where NO competitively binds to complexes I and IV of the respiratory chain (6, 7). 
However, if the primary effect of NO2
- on PO2mv is mitochondrial inhibition, then a continuous 
increase in steady-state PO2mv during muscle contractions would be expected but clearly this is 
not found (Figure 4A). It is pertinent that using a similar protocol with SNP, Hirai and colleagues 
(25) demonstrated the integrity of mitochondrial respiration (and thus V̇O2) concomitant with 
elevated NO2
- and NO. Thus, the elevation in baseline PO2mv seen herein is most likely the 
consequence of enhanced blood flow and Q̇O2 rather than decreased V̇O2.  
The heightened vascular response and increased QO2 with NaNO2 superfusion (11, 28, 
46) persists into the onset of contractions (slowed PO2mv kinetics) as demonstrated in Figures 
4A and 4B.  In Figure 4B the rate at which PO2mv is falling is slowed by disproportionate 
changes in Q̇O2 and V̇O2 across the initial 40 seconds. Enhancing the Q̇O2-to-V̇O2 relationship at 
this crucial transition would potentially improve energy production via oxidative metabolism, 
15 
decrease the acidic sequelae of glycolytic pathways, and delay the onset of fatigue processes (29, 
50).  
 
 Potential Therapeutic Significance 
NO2
- precursors such as NO3
- containing beetroot juice effectively increase plasma [NO2
-
] and can improve exercise performance in healthy individuals (1, 32, 53) and patient populations 
where cardiovascular function is impaired such as CHF (54) and peripheral artery disease (PAD) 
(31).  Specifically, CHF patients have an increased cardiac output reserve secondary to the 
reduction of vascular resistance (54). Likewise, PAD patients exhibit improved exercise/walking 
performance and delayed onset of claudication following beetroot juice supplementation (31).  
However, elevating circulating [NO2
-] via dietary means takes 2-3 hours which may constitute 
too great a delay for an effective therapeutic outcome. A potential alternative is oral 
administration of NaNO2 which elevates circulating [NO2
-] within 30 minutes in older adults 
(14) and diabetic patients (24).  More direct routes of NaNO2 (i.e. intravascular infusion or oral 
administration) can bypass the need for bacterial breakdown of NO3
- and absorption in the gut 
and increase vascular [NO2
-] rapidly. Thus, i.v. NO2
- infusions have improved cardiac function 
and exercise performance in CHF patients (5). Additionally, NO2
- infusion during L-NAME 
induced NOS blockade or CHF (18, 23) reverses the consequences of absent endogenous NO 
bioavailability and provides an avenue for enhanced Q̇O2-to-V̇O2 matching.  
Administration of NaNO2 protects against hypoxic damage to liver, cerebral, and 
myocardial tissue via the reduction of NO2
- to NO (17, 30, 47, 49), but possibly not the kidney 
(3, 48). Therefore topical administration of NaNO2, potentially via implantable osmotic micro-
pump, may provide tissue protection during acute surgical or other medical conditions by 
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elevating Q̇O2 and PO2mv within 3 minutes of application (see Figure 3) without confounding 
peripheral vascular effects (i.e. reductions in tissue PO2mv [Figure 1] that are coincident with 
reductions in MAP [Figure 2]). Local administration may open up the avenue for long-term 
administration at a desired location enhancing Q̇O2 and PO2mv for extended durations.  The 
progressive decay of NO2
-‘s effects on PO2mv (Figures 1 and 4B) indicates that setting the 
required [NaNO2] and timing of application would be crucial. 
 
 Experimental Considerations 
Although PO2mv was significantly different at rest and the beginning of muscle 
contractions, the effect of NO2
- is largely diminished by the time the steady-state PO2mv is 
reached (Figure 4A and 4B).  It remains unclear whether this is a direct effect of NO2
- wearing 
off irrespective of muscle contractions, or whether contractions and the attendant hypoxia are 
elevating NO2
- utilization. Figure 1 demonstrates that in the absence of muscle contractions, 
PO2mv plateaus and then declines at a rate of ~0.7 mmHg min
-1 after superfusion has ceased.  
This would indicate, in part, why NaNO2 superfusion does not enhance steady-state PO2mv 
relative to the control condition.  Importantly, the linear decay in PO2mv sheds light on the 
utilization of NO2
- in the absence of systemic circulation which continually delivers NO2
- stores. 
Future investigations into various delivery methods of NaNO2 (i.e. injectable pellets or cutaneous 
patches) may be warranted considering that the administration of NO2
- augments PO2mv at rest 
and during the rest-exercise transition.  
 
 Conclusion 
NaNO2 serves therapeutically as a hypoxic vasodilator with efficacy for improving 
exercise performance in patients with cardiovascular disease (1, 5, 36, 41, 42). The present 
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investigation demonstrates the ability of NaNO2 to locally elevate skeletal muscle PO2mv at rest 
and following the onset of contractions in the healthy rat without altering MAP. Enhancing the 
muscle vascular O2 driving pressure via NaNO2 would provide a fast-acting modality to 
potentially improve metabolic control and thus delay fatigue and/or hypoxic damage.  Improving 
PO2mv dynamics alongside what remains of the endogenous NOS system under these conditions, 
NaNO2 may ameliorate perturbations in the Q̇O2-to-V̇O2 ratio commonly found in disease states 
such as CHF and PAD. Fast-acting improvements in both resting and exercise PO2mv dynamics 
may add to the current standard of care in populations with limited exercise tolerance along with 
individuals that may be suffering from focal tissue hypoxia and/or ischemia (i.e. frostbite, PAD, 
stroke).  
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